THE TWILIGHT OF ANTIBIOTICS:

Keywords

Abstract

References

1. [1]References
2. [2]1- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Murray, C. J. L. et al. Lancet 399, 2022.
3. [3]2- Global burden of bacterial antimicrobial resistance in 2019: summary and implications. BMJ (2022).
4. [4]3- Review on Antimicrobial Resistance. Aslam, B. et al. Antibiotic Resistance: One Health One World Outlook. O’Neill, J. Front. Cell. Infect. Microbiol., 2021.
5. [5]4- Ranjbar, R. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Infect Control Hosp Epidemiol. 2016 doi: 10.1017/ice.2016.168.
6. [6]5- Multidrug Resistant Bacteria in the Community: Trends and Lessons Learned.” Van Duin, D. & Paterson, D. L. Infect. Dis. Clin. North Am., 2016.
7. [7] 6- Antimicrobial use, healthcare associated infections, and bacterial resistance in general hospitals in China: the first national pilot point prevalence survey report.” Eur. J. Clin. Microbiol. Xiao, Y. et al. Infect. Dis., 2023.
8. [8]7- Patterns of multi drug resistant bacteria at first culture from patients admitted to a third level university hospital in Calabria from 2011 to 2014. Reale, M. et al. Infez. Med., 2017.
9. [9]8- Risk Factors for Gastrointestinal Colonization and Acquisition of Carbapenem-Resistant Gram-Negative Bacteria among Patients in Intensive Care Units in Thailand Antimicrob Agents. Anong Kiddee et al. Chemother. 2018
10. [10]9 -Colonization pressure: a critical parameter in the epidemiology of antibiotic resistant bacteria. Bonten, M. J. M. Crit. Care, 2012.
11. [11]10- Global, regional, and national burden of bacterial carbapenem resistance from 1990 to 2021 and predictions up to 2035. Jie-Hao Tai, Yi-Le Wu et al. Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2025.107636.
12. [12]11- ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics | Nature Reviews Microbiology. William R. Miller & Cesar A. Arias. Nature Reviews Microbiology volume 22, pages598–616 (2024)
13. [13]12- Epidemiological investigation and patterns of antimicrobial use in multidrug-resistant bacteria at a tertiary hospital: a retrospective cohort study. Man Wang, Qiang Fu. BMJ Open doi: 10.1136/bmjopen-2025-099847
14. [14]13- Predicting antimicrobial resistance of bacterial pathogens using time series data from >600 farms. Kim, J. et al. Front. Microbiol., 2023.
15. [15]14- Time series analysis of antibacterial usage and bacterial resistance in China: observations from a tertiary hospital from 2014 to 2018. PLoS One, 2019.
16. [16]15- Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta analysis. Zhou, R. et al. BMJ Open, 2021.
17. [17]16- Clinical epidemiology of carbapenem resistant Enterobacterales in the Greater Houston region of Texas: a 6 year trend and surveillance analysis. Tadese, B. K. et al. J. Glob. Antimicrob. Resist., 2022.
18. [18]17- Surveillance of carbapenem resistant Klebsiella pneumoniae in Chinese hospitals – A five year retrospective study. Qu, X. et al. J. Infect. Dev. Ctries., 2019.
19. [19]18- Carbapenem Resistant Klebsiella pneumoniae in Large Public Acute Care Healthcare System, New York, New York, USA, 2016–2022. Lee, J. et al. Emerg. Infect. Dis., 2023.
20. [20]19- Healthcare associated carbapenem resistant Klebsiella pneumoniae infections are associated with higher mortality compared to carbapenem susceptible K. pneumoniae infections in the intensive care unit. Yao, Y. et al. J. Hosp. Infect., 2024.
21. [21]20- Epidemiology of carbapenem resistant Enterobacteriaceae. Chotiprasitsakul, D. et al. Infect. Drug Resist., 2019.
22. [22]21- Chatzopoulou M, Reynolds L. Systematic review of the effects of antimicrobial cycling on bacterial resistance rates within hospital settings. Br J Clin Pharmacol. 2022;88(3):897-910. doi:10.1111/bcp.15042
23. [23]22- Antibiotic Cycling Affects Resistance Evolution Independently of Collateral Sensitivity. Brepoels P, Appermans K, Pérez-Romero CA, Lories B, Marchal K, et al. Mol Biol Evol. 2022 Dec 5;39(12):msac257. doi:10.1093/molbev/msac257. (Open access via PMC: PMC9778841).
24. [24]23- Multidrug resistant, extensively drug resistant and pandrug resistant bacteria: an international expert proposal for interim standard definitions. Magiorakos, A. P. et al. Clin. Microbiol. Infect., 2012.
25. [25]24- Carbapenem resistant Enterobacteriaceae: epidemiology and management. E. Temkin, A. Adler, A. Lerner, Y. Carmeli Clin. Microbiol. Rev., 2014. DOI: 10.1111/nyas.12537
26. [26]25- Carbapenem resistant Klebsiella pneumoniae: a global threat. Expert Rev. Anti Infect. Ther., 2020.
27. [27]26- Molecular and clinical epidemiology of carbapenem resistant Acinetobacter baumannii ST2 in Oceania: a multicountry cohort study. S. C. Baleivanualala, S.V. Devi, B. Howden, C.L. Gorrie, S. Matanitobua et al. Lancet Inf Dis. 2017.
28. [28]27- Carbapenem resistant Pseudomonas aeruginosa. Front. Microbiol., 2019.
29. [29]28- Methicillin resistant Staphylococcus aureus (MRSA): a global perspective. Lancet Infect. Dis., 2016.
30. [30]29- Vancomycin resistant Enterococcus (VRE): epidemiology and outcomes. Clin. Microbiol. Rev., 2019.
31. [31]30- Pandrug resistant Acinetobacter baumannii: emergence and clinical implications. J. Infect., 2018.
32. [32]31- Pandrug resistant Gram negative pathogens in the ICU. Crit. Care, 2021.
33. [33]32- Pan drug resistant Pseudomonas aeruginosa: a case report and review. J. Infect. Public Health, 2019.
34. [34]33- Extensively drug resistant tuberculosis (XDR TB): global epidemiology. Lancet, 2018.
35. [35]34- Pandrug resistant Klebsiella pneumoniae producing carbapenemases in a European ICU. Antimicrob. Agents Chemother., 2020.
36. [36]35- Pandrug resistant Enterobacter spp. in a teaching hospital. J. Glob. Antimicrob. Resist., 2021
37. [37]36- Extensively drug-resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features, and outcomes. Che-Kim Tan et al. Diagnostic Microbiology and Infectious Disease, 2008 10.1016/j.diagmicrobio.2007.09.007
38. [38]37- https://pubmed.ncbi.nlm.nih.gov/?term=antibiotic+resistance
39. [39]38- Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032). https://univdatos.com/reports/antibiotic-resistance-market
40. [40]39- Inhibition of sugar uptake by ascorbic acid in Escherichia coli. Loewen PC, Richter HE. Arch Biochem Biophys. 1983;226(2):657–665.
41. [41]40 -Alternate pathway to ascorbate induced inhibition of Mycobacterium tuberculosis. Shukla H, Tripathi A, Shukla S. Tuberculosis (Edinb). 2018;111:161–169.
42. [42]41- 2 Deoxy D glucose is a potent inhibitor of biofilm growth in Escherichia coli. Hoffman PS, et al. Microbiology. 2016;162(6):1037–1046.
43. [43]42- Regulation of glycolysis and sugar phosphotransferase activities in Streptococcus lactis: growth in the presence of 2 deoxy D glucose. Thompson J, Chassy BM. J Bacteriol. 1982;149(1):183–193.
44. [44]43- Antimetabolites in the Treatment of Solid Tumors: Competitive Inhibition by Structural Analogs. Prieto Gratacós, Ernesto. Journal of Oncology Research and Therapy, 2026. doi:10.29011/2574-710X.10342.
45. [45]44- Activity of the Lactate Dehydrogenase Inhibitor Oxamic Acid against the Fermentative Bacterium Streptococcus mitis/oralis: Bactericidal Effects and Prevention of Daptomycin Resistance. R. Kebriaei et al. Antibiotics, (2022) DOI: 10.3390/antibiotics11101409
46. [46]45- Energy Conservation in Fermentations of Anaerobic Bacteria. Wolfgang Buckel. Frontiers in Microbiology, (2021) DOI: 10.3389/fmicb.2021.703525
47. [47]46- Kinetic characterization of annotated glycolytic enzymes present in cellulose-fermenting Clostridium thermocellum suggests different metabolic roles. S.R. Daley et al. Biotechnology for Biofuels and Bioproducts, (2023) DOI: 10.1186/s13068-023-02362-8
48. [48]47- Safety of Antimetabolite 2-Deoxy-D-arabinohexose (2DG) as a Coadjuvant Metabolic Intervention in 268 Cancer Patients. Prieto Gratacós E. Cancer Medicine Journal. 2020;
49. [49]48- - The wonders of 2 deoxy D glucose. Xi J, et al. IUBMB Life. 2014;66(2):73–80.
50. [50]49- Evaluation of antibacterial activity of vitamin C against human bacterial pathogens. Braz J Biol. 2021;82:e243836.
51. [51]50- Reversal of the Pathophysiological Responses to Gram-negative Sepsis by Megadose Vitamin C** by Y.R. Lankadeva et al. Critical Care Medicine, (2021) DOI: 10.1097/CCM.0000000000004778
52. [52]51- Chloroquine Inhibits Autophagy, Enhances p53-Dependent Apoptosis, and Delays Tumor Recurrence in a Mouse Model of B Cell Lymphoma. RK. Amaravadi, A. Thomas-Tikhonenko, CB. Thompson. Blood 2005. doi.org/10.1182/blood.V106.11.2421.2421
53. [53]52- The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis. Xu, Ran; Ji, Ziyi; Xu, Chen; Zhu, Jing MD. Medicine, 2018. DOI: 10.1097/MD.0000000000012912
54. [54]53- Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Cook KL, Wärri A, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A, Clarke R. Clin Cancer Res. 2014 doi: 10.1158/1078-0432.CCR-13-3227.

Authors (2)